PE20191614A1 - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo - Google Patents

Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo

Info

Publication number
PE20191614A1
PE20191614A1 PE2019001541A PE2019001541A PE20191614A1 PE 20191614 A1 PE20191614 A1 PE 20191614A1 PE 2019001541 A PE2019001541 A PE 2019001541A PE 2019001541 A PE2019001541 A PE 2019001541A PE 20191614 A1 PE20191614 A1 PE 20191614A1
Authority
PE
Peru
Prior art keywords
seq
cognitive disorders
treat
antibody
prevent cognitive
Prior art date
Application number
PE2019001541A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Takashi Murakami
Naoko Namiki
Akira Tanokura
Jeanne E Baker
Batteur Sophie Parmentier
Angela Marie Jablonski
Daniel Stephen Malashock
Carl Mieczkowski
Gopalan Raghunathan (Raghu)
Original Assignee
Teijin Pharma Ltd
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Merck Sharp & Dohme filed Critical Teijin Pharma Ltd
Publication of PE20191614A1 publication Critical patent/PE20191614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Referido a un anticuerpo anti fosforilado anti-pSer413 tau, el cual se une a la proteina tau fosforilada en el residuo de serina 413, que comprende: a) un dominio variable pesado seleccionado de SEQ ID NO: 116 y SEQ ID NO: 117; b) un dominio variable ligero seleccionado de SEQ ID NO: 114, SEQ ID NO: 104, entre otras; c) un dominio constante pesado seleccionado de SEQ ID NO: 135, SEQ ID NO: 136, entre otras y d) un dominio constante ligero seleccionado entre SEQ ID NO: 79 y SEQ ID NO: 80. Ademas se refiere a una composicion de acido nucleico que comprende: a) un primer acido nucleico que codifica una cadena ligera seleccionada de SEQ ID NO: 162, SEQ ID NO: 163, entre otras; y b) un segundo acido nucleico que codifica una cadena pesada seleccionada de SEQ ID NO: 144; SEQ ID NO: 145, entre otras; un vector, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo. Dicho anticuerpo tiene una afinidad selectiva con la proteina tau fosforilada y presenta antigenicidad reducida para el cuerpo humano, siendo util para el tratamiento de trastornos cognitivos, como la enfermedad del Alzheimer.
PE2019001541A 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo PE20191614A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
PCT/IB2018/000249 WO2018154390A1 (en) 2017-02-27 2018-02-27 Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Publications (1)

Publication Number Publication Date
PE20191614A1 true PE20191614A1 (es) 2019-11-05

Family

ID=62025891

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001541A PE20191614A1 (es) 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo

Country Status (26)

Country Link
US (3) US10556950B2 (es)
EP (1) EP3585810A1 (es)
JP (3) JP2018139530A (es)
KR (1) KR20190122674A (es)
CN (2) CN110382528A (es)
AR (2) AR110875A1 (es)
AU (1) AU2018224390A1 (es)
BR (1) BR112019016490A2 (es)
CA (1) CA3052538A1 (es)
CL (2) CL2019002296A1 (es)
CO (1) CO2019008786A2 (es)
CR (1) CR20190363A (es)
DO (1) DOP2019000215A (es)
EA (1) EA201991726A1 (es)
GE (1) GEP20227392B (es)
IL (1) IL267945A (es)
JO (1) JOP20180014A1 (es)
MA (1) MA47608A (es)
MX (1) MX2019009945A (es)
MY (1) MY193821A (es)
NI (1) NI201900086A (es)
PE (1) PE20191614A1 (es)
PH (1) PH12019501929A1 (es)
SG (2) SG11201907548PA (es)
TW (1) TW201843179A (es)
WO (2) WO2018154392A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
TWI780464B (zh) * 2019-08-06 2022-10-11 香港商新旭生技股份有限公司 結合至病理性ｔａｕ種類之抗體及其用途
AR122499A1 (es) * 2020-06-02 2022-09-14 Teijin Pharma Ltd Anticuerpo humanizado anti-receptor de igf-1
AR122721A1 (es) 2020-06-25 2022-09-28 Merck Sharp & Dohme Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US7754497B2 (en) 2003-08-29 2010-07-13 Reverse Proteomics Research Institute Co., Ltd. Method for immobilizing proteins
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
JP6306513B2 (ja) 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用
DK2857039T3 (da) 2012-05-31 2019-12-16 Univ Osaka City Terapeutisk middel eller profylaktisk middel mod demens
MX359817B (es) * 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
EA035932B1 (ru) 2012-12-21 2020-09-02 Байоджен Ма Инк. Человеческие анти-тау антитела
PL3007726T3 (pl) 2013-06-10 2021-01-11 Ipierian, Inc. Metody leczenia tauopatii
PL3083680T3 (pl) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
MA41669A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
US10287343B2 (en) 2015-07-06 2019-05-14 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Also Published As

Publication number Publication date
EP3585810A1 (en) 2020-01-01
KR20190122674A (ko) 2019-10-30
JP2018139530A (ja) 2018-09-13
US11739143B2 (en) 2023-08-29
US20200223916A1 (en) 2020-07-16
TW201843179A (zh) 2018-12-16
AR110875A1 (es) 2019-05-08
GEP20227392B (en) 2022-06-27
MY193821A (en) 2022-10-27
JP2020508666A (ja) 2020-03-26
CN110382528A (zh) 2019-10-25
IL267945A (en) 2019-09-26
DOP2019000215A (es) 2019-09-30
CN111320695B (zh) 2021-09-03
CL2021002389A1 (es) 2022-04-22
SG10201913419TA (en) 2020-03-30
US10556950B2 (en) 2020-02-11
MA47608A (fr) 2020-01-01
AR117952A2 (es) 2021-09-08
PH12019501929A1 (en) 2020-06-29
AU2018224390A1 (en) 2019-07-11
US20210380677A1 (en) 2021-12-09
EA201991726A1 (ru) 2020-01-30
US20180346564A1 (en) 2018-12-06
SG11201907548PA (en) 2019-09-27
BR112019016490A2 (pt) 2020-04-07
NI201900086A (es) 2019-10-08
JP2023002670A (ja) 2023-01-10
MX2019009945A (es) 2019-11-05
CN111320695A (zh) 2020-06-23
CR20190363A (es) 2019-11-05
US10894829B2 (en) 2021-01-19
JOP20180014A1 (ar) 2019-01-30
CL2019002296A1 (es) 2019-11-29
CO2019008786A2 (es) 2019-08-20
JP7165996B2 (ja) 2022-11-07
WO2018154390A1 (en) 2018-08-30
WO2018154392A1 (en) 2018-08-30
CA3052538A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
EA202091710A1 (ru) Антитела против cd73 и способы их применения
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
WO2016191643A3 (en) Tigit-binding agents and uses thereof
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
PE20180481A1 (es) Anticuerpos de union a tau
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
WO2015187521A3 (en) Anti-blys antibodies
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.